Demonstrates improved catalytic performance of d-allulose production in engineered biocatalysts, implying potential for industrial applications.
d-Allulose, a low-calorie, rare monosaccharide with sucrose-like sweetness, has emerged as a promising alternative to traditional sweeteners. However, its industrial-scale production remains hindered by the limited thermostability and operational longevity of the key biocatalysts d-allulose 3-epimerase (DAE). To address this bottleneck, this study engineered a DAE from Clostridium cellulolyticum H10 (CcDAE) by targeting its flexible loop 106-121 for improving thermostability. Through directed evolution, an advantageous mutant, T119K, was identified. Subsequent combinatorial mutagenesis yielded a superior triple mutant, T119K/D281G/C289R, which exhibited a significantly enhanced performance. Furthermore, to bridge the gap between laboratory-scale optimization and industrial application, a whole-cell immobilization strategy was implemented by expressing this mutant in Bacillus subtilis, the robust biocatalyst maintained remarkable activity over 64 reusable cycles. This breakthrough not only provides a highly thermostable DAE mutant but also establishes an efficient and scalable bioprocess for sustainable d-allulose production, offering critical theoretical insights and support for the food industries.
No takes yet. Share an insight, caveat, or question.
Liu et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: